Despite improvements in the outcome of therapy for ALL 1 , this disease remains the most common cause of cancer-related death in young people. Genomic profiling has identified submicroscopic genetic alterations in ALL that are key determinants of leukemogenesis-notably, alterations in B-lymphoid transcription factors in B-progenitor ALL (B-ALL) 2,3 . Moreover, specific genetic alterations are associated with treatment failure in ALL, including alterations of IKZF1 (refs. 4,5) and CREBBP 6 . However, the genetic basis of several subtypes 
A r t i c l e s of high-risk ALL remains poorly understood. Notably, hypodiploid ALL with fewer than 44 chromosomes is characterized by multiple whole-chromosomal losses and extremely poor outcomes [7] [8] [9] [10] [11] . Hypodiploid ALL may be subclassified into near-haploid cases with 24-31 chromosomes, low-hypodiploid cases with 32-39 chromosomes and, less commonly, high-hypodiploid cases with 40-43 chromosomes 11 . Furthermore, the hypodiploid genome may undergo reduplication, resulting in a hyperdiploid karyotype (known as 'masked' hypodiploid ALL) 12 . In contrast, near-diploid cases with 44-45 chromosomes commonly harbor dicentric chromosomes or other known chromosomal rearrangements (for example, ETV6-RUNX1) 10 and do not share the poor outcomes of hypodiploid ALL with more severe aneuploidy. Few hypodiploid ALL cases have been studied in previous genomic analyses, and those that have been investigated typically have 45 chromosomes, dicentric chromosomes or both 3 .
Here we report the results of microarray profiling of geneexpression and copy-number alterations, and Sanger and nextgeneration sequencing analysis of 124 childhood hypodiploid ALL cases. We have identified multiple recurring genetic alterations that distinguish near-haploid and low-hypodiploid ALL and that are rare or absent in other ALL subtypes. Genetic alterations involving TP53, RB1 and the IKAROS gene-family member IKZF2 are hallmarks of low-hypodiploid ALL; in contrast, most cases of near-haploid ALL harbor alterations targeting receptor tyrosine kinase (RTK) signaling and Ras signaling and show a high frequency of IKZF3 alterations. Notably, the TP53 alterations observed in 91.2% of childhood cases of low-hypodiploid ALL are also present in nontumor cells in 43 .3% of the mutation-carrying cases, suggesting that these mutations are inherited and that low-hypodiploid ALL represents a manifestation of Li-Fraumeni syndrome (LFS) 13, 14 . Moreover, hypodiploid ALL cells show activation of Ras and PI3K signaling and are sensitive to PI3K inhibitors, suggesting that these agents represent a new therapeutic strategy in this high-risk disease.
RESULTS

Genomic overview of the hypodiploid ALL cohort
We studied the leukemic blasts from 124 children with hypodiploid ALL, 89 of which had matched remission DNA available (Supplementary Table 1 ). This cohort included 50 near-haploid cases; 18 cases with evidence of doubling of the near-haploid clone, either as the sole population (that is, masked hypodiploidy) or with both nondoubled and a pronounced doubled population; 26 low-hypodiploid Masked hypodiploid cases here refer to cases with either a pure doubled-hypodiploid clone or cases harboring a doubled clone constituting at least 30% of leukemic cells. Indel, insertion-deletion; aa, amino acid; CDS, coding DNA sequence; UTR, untranslated region; HQ, high quality; tier 1, variants in coding regions, splice sites, UTRs and noncoding RNAs; tier 2, variants in conserved regions; tier 3, variants in nonrepeat regions; tier 4, all other variants.
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A r t i c l e s cases; and 8 masked or partially masked low-hypodiploid cases.
We also studied 22 near-diploid cases, most of which had a dicentric chromosome, and a cohort of 117 adult ALL cases, including 11 lowhypodiploid cases (Supplementary Table 2 ).
We performed whole-genome or exome sequencing of tumor and matched remission DNA for 25 pediatric near-haploid cases (11 whole genome and 14 exome) and 15 pediatric low-hypodiploid cases (9 whole genome and 6 exome; Fig. 1, Supplementary Fig. 1 and Supplementary Tables 1, 3 In contrast to other recently published whole-genome sequencing data examining high-risk T-cell leukemia, we identified no complex rearrangements in hypodiploid ALL 15 .
We used Affymetrix SNP 6.0 microarrays to carry out genome-wide profiling of DNA copy-number alterations and loss of heterozygosity for leukemic and remission samples for all cases and Affymetrix U133 Plus 2.0 microarrays to carry out gene expression profiling (Fig. 2) Table 9) . The most common targets of aneuploidy were chromosomes 1-7, 9, 11-13, 15-17, 19-20 and 22 in near-haploid ALL and chromosomes 2-4, 7, 9, 12-13, 15-17 and 20 in low-hypodiploid ALL (Fig. 2a) , as has been previously shown by cytogenetic analyses 11 . Notably, both copies of chromosome 21 were always retained. Figure 2 Genome-wide DNA copy-number alterations and gene expression profiling of hypodiploid ALL. (a) Log 2 ratio DNA copy-number heatmap showing SNP 6.0 microarray data for the tumor samples from the pediatric hypodiploid ALL cohort. Chromosomes 1-22, X and Y are depicted from top to bottom, and individual samples are shown from left to right. An asterisk indicates tumor samples with <70% blasts. LH, low hypodiploid. Blue indicates deletions, and red indicates amplifications. Dicentric chromosomes most frequently involved chromosome arms 9p and either 12p or 20q, and were observed predominantly in near-diploid karyotypes. Copy-neutral loss of heterozygosity was observed for diploid chromosomes in masked hypodiploid cases (supplementary Fig. 2 and supplementary table 10 ), consistent with duplication of the hypodiploid clone. (b) Left, unsupervised principal component analysis (PCA) of gene expression data from all hypodiploid ALL cases with available high-quality RNA (n = 94). PCA using 1,000 representative probe sets selected by k means distinguishes near-haploid and masked near-haploid ALL, low-hypodiploid and masked low-hypodiploid ALL, and the near-diploid ALL subroup. Right, weighted pair-group method with arithmetic mean hierarchical clustering analysis performed using the 10,000 most variable probe sets. Masked hypodiploid cases here refer to cases with a doubled hypodiploid clone constituting at least 30% of leukemic cells. Table 1 ). In contrast, low-hypodiploid ALL was enriched for alterations of TP53 (91.2%), RB1 (41.2%) and IKZF2 (52.9%; Table 1 ). Adult low-hypodiploid ALL also had a high frequency of TP53 mutations (90.9%), indicating that mutations of TP53 are a hallmark of lowhypodiploid ALL (Supplementary Table 16 ).
Mutations targeting RTK and Ras signaling in near-haploid ALL
More than two-thirds (70.6%) of near-haploid ALL cases harbored genetic alterations known or predicted to result in activation of RTK or Ras signaling, including deletion, amplification and/or sequence mutation of NF1, NRAS, KRAS, MAPK1, FLT3 or PTPN11. RTK-and Ras-signaling alterations were less frequent in low-hypodiploid (8.8%) and near-diploid ALL (31.8%, P = 2.47 × 10 −5 ; Fig. 3 , Table 1 and Supplementary Table 12 ).
Thirty of 68 near-haploid cases (44.1%) had focal deletions or sequence mutations of NF1 ( Fig. 3a and Supplementary Table 12) . Because of aneuploidy, the NF1 alterations were biallelic in 76.7% of near-haploid cases. Neurofibromin, encoded by NF1, is a tumor suppressor, Ras-GTPase-activating protein and negative regulator of Ras signaling 16 . Alterations of NF1 result in neurofibromatosis [16] [17] [18] [19] and juvenile myelomonocytic leukemia 20 . NF1 alterations also occur in T-lineage ALL, acute myeloid leukemia 21 and nonhematopoietic malignancies such as glioblastoma 22 . Furthermore, neurofibromatosis is associated with an increased risk of developing leukemia 23, 24 .
In contrast to other tumors, in which NF1 deletions usually involve the entire gene 25 , we found that the focal NF1 deletions in hypodiploid ALL were always intragenic, involving exons 15-35 in 17 of 21 cases (Fig. 3b,c, Supplementary Fig. 5 and Supplementary Table 12 ). To our knowledge, this focal deletion has not previously been described and results in deletion of the GTPase-activating protein domain. Sequencing of the genomic breakpoints suggests that these deletions result from aberrant recombinase-activating gene activity ( Fig. 3c and Supplementary Fig. 5b ), which has been implicated in the generation of other chromosomal rearrangements and deletions in ALL 26, 27 .
To characterize further the transcriptional consequences of the NF1 exon 15-35 deletion, we performed RT-PCR for NF1 in 17 hypodiploid ALL cases and mRNA sequencing of NALM-16 cells (ref. 28 ), a near-haploid cell line harboring the same deletion of NF1 exons 15-35. The deletion results in splicing of exons 14 to 36, causing a frameshift in exon 36 ( Fig. 3d and Supplementary Fig. 5 ). Immunoblotting of NALM-16 cells indicated that the deletion results in loss of NF1 expression (Supplementary Fig. 6 ). 
A r t i c l e s
We identified RTK and Ras pathway alterations in matched nontumor DNA from two near-haploid cases (Supplementary Fig. 7) . A PTPN11 p.Gly503Arg substitution (case SJHYPO036) was heterozygous in remission DNA and homozygous in the tumor as a result of aneuploidy. This substitution has been reported previously as a somatic and inherited variant in juvenile myelomonocytic leukemia and Noonan syndrome and is located in a mutational hotspot region in hematopoietic malignancies and Noonan syndrome 29, 30 . Exchange of this amino acid results in constitutive activation of the phosphatase 29 . We identified an NRAS p.Gly12Ser substitution in remission DNA from case SJHYPO020 and verified it in this patient by sequencing DNA from normal T cells purified from bone marrow (Supplementary Fig. 7 ). Inherited NRAS mutations are rare in hematopoietic disorders 31 and have not previously been described in ALL. The p.Gly12Ser alteration may have a lower transforming potential than other NRAS Gly12 alterations and may therefore be tolerated as inherited 32 . These results suggest either an inherited predisposition to leukemia or acquisition of the RTK and Ras pathway mutations as de novo germline mutations or in a primitive hematopoietic progenitor cell in these patients.
Recurrent alterations of PAG1 in near-haploid ALL PAG1, encoding phosphoprotein associated with glycosphingolipid microdomains 1, also known as Csk-binding protein (CBP), was altered in 10.3% of near-haploid ALL but was rarely altered in the other hypodiploid ALL subtypes (Supplementary Tables 1 and 17) . Mutations in this gene have not previously been described in leukemia. Most PAG1 deletions were homozygous and involved the upstream region and first exon, leading to a complete loss of PAG1 expression (Supplementary Fig. 8 ).
PAG1 is known mainly as an adaptor for C-terminal Src kinase in T cells, thereby having a role in the negative regulation of Src family kinases [33] [34] [35] . PAG1 has also been identified as a putative Ras-signaling inhibitor 36 and has a negative regulatory function in proximal B cell-receptor signaling 37 .
TP53 mutations in low-hypodiploid ALL One notable observation was the presence of TP53 alterations in 91.2% of pediatric low-hypodiploid ALL compared to in <5% of non-low-hypodiploid B-ALL 38,39 (P = 1.65 × 10 −20 ; Fig. 4 , Table 1 and Supplementary Table 18 ). Thirty (88.2%) cases had a sequence mutation, most of which were homozygous as a result of aneuploidy. Using RT-PCR, we identified an additional case that expressed an aberrantly spliced isoform lacking exons 2-6, including the translational start site, with no expression of the wild-type allele (data not shown). The TP53 mutations included missense, nonsense and insertion-deletion mutations and are, in general, predicted to be lossof-function mutations ( Fig. 4a and Supplementary Table 18 ).
Almost half (43.3%) of the TP53 mutations in pediatric lowhypodiploid ALL were present in nontumor hematopoietic cells (Supplementary Table 18 ), which is suggestive of an inherited origin or acquisition as de novo mutations in the germline or hematopoietic compartment (a comprehensive listing of putative deleterious sequence variants present in nontumor cells is provided in the Supplementary Note and Supplementary Table 7) . Moreover, many of the mutations have previously been reported as being associated with LFS 40 . The most common LFS substitution, p53 p.Arg248Trp, was present in three low-hypodiploid cases. This mutation prevents p53 from binding into the minor groove of its DNA-binding site 41 . Furthermore, the Arg306* alteration present in three cases has previously been identified as both somatic and inherited 40 .
In support of an inherited origin of the TP53 mutations, we studied a kindred in which a child with low-hypodiploid ALL harbored a p53 Gly302 frameshift alteration that was homozygous in leukemic cells and heterozygous in a skin biopsy lacking tumor involvement (Fig. 4c,d and Supplementary Note). The proband's father developed glioblastoma multiforme, an LFS-associated malignancy, and we identified the same homozygous mutation in a tumor sample from the father obtained at diagnosis (Fig. 4d-e) .
We also identified TP53 mutations in 10 of 11 adult low-hypodiploid cases (90.9%) but only 8 of 106 (7.5%) non-low-hypodiploid ALL cases (P = 5.03 × 10 −9 ; Fig. 4b and Supplementary Tables 2 and 16 ). (Fig. 4f,g, Supplementary  Fig. 9 and data not shown). Expression of CDKN1A, encoding the cyclin-dependent kinase inhibitor p21, is directly regulated by p53 (ref. 45) . We confirmed inactivity of one of the p53 mutants (p.Arg280Ser, xenograft SJHYPO120-X) by showing a lack of increase in p21 expression after treatment of the leukemia cells with etoposide (Supplementary Fig. 9a ). 
Frequent deletions of IKZF2 and IKZF3 in hypodiploid ALL
Alteration of IKZF1 is a hallmark of high-risk, non-hypodiploid B-ALL 5,27,39 , but alteration of other IKAROS-family genes is rare. In contrast, IKZF1 alterations were infrequent in hypodiploid ALL, whereas deletion of IKZF2 was common in low-hypodiploid ALL (18 of 34 cases, 52.9%; Fig. 5 and Supplementary Table 17) . IKZF2 deletions were also common in adult low-hypodiploid ALL, with 4 of 11 cases (36.4%) harboring deletions compared to 2 of 106 adult non-low-hypodiploid ALL cases (1.9%, P = 0.0005; Supplementary  Fig. 10 and Supplementary Table 19) .
Alterations of IKZF3 were common in near-haploid ALL, with deletions and one frameshift mutation in 9 of 68 cases (13.2%), but were rare in non-near-haploid ALL (P = 0.061; Fig. 5c and Supplementary Table 17 ). Alterations of IKZF2 and IKZF3 were biallelic as a result of aneuploidy (Supplementary Table 12 ).
The IKAROS gene family encodes zinc-finger transcription factors involved in lymphoid development and differentiation 46 . The founding member IKZF1 is essential for lymphopoiesis, and Ikzf1 inactivation in mice leads to a complete lack of B-lymphoid cells 47, 48 . Aiolos has a key role in B-cell differentiation and associates with Ikaros in an Ikarosnucleosome remodeling and deacetylase (NuRD) complex 49 , whereas Helios has a role in regulatory T-cell development [50] [51] [52] . During B-cell development, Ikzf2 expression is highest in common lymphoid progenitors and pre-pro-B cells, whereas Ikzf3 expression is highest in more mature lymphoid precursors 53, 54 (Supplementary Fig. 11 ), suggesting that the alterations of IKZF2 and IKZF3 in low-hypodiploid and near-haploid ALL, respectively, occur in cells at different stages of lymphoid maturation. Accordingly, the frequency of antigen-receptor rearrangements and expression of CD19 are lower in low-hypodiploid ALL than in non-low-hypodiploid B-ALL (Supplementary Fig. 12a-c) . Furthermore, low-hypodiploid cases have a similar transcriptional profile to immature mouse lymphoid progenitors (Hardy stage B; Supplementary Fig. 12d ). Together these observations suggest that low-hypodiploid ALL arises from transformation of a less mature lymphoid progenitor than that from which near-haploid ALL arises.
RB1 alterations in low-hypodiploid ALL
Alterations of RB1 were present in 14 of 34 (41.2%) low-hypodiploid cases compared to 6 of 68 (8.8%) near-haploid cases and were absent in near-diploid ALL (P = 1.19 × 10 −5 ; Table 1 and Supplementary  Fig. 13a,b) . Thirteen (92.9%) RB1-altered low-hypodiploid cases had concomitant TP53 mutations, whereas only one (7.1%) had co-occurrence of alterations in RB1 and CDKN2A and CDKN2B. A total of 61.8% of low-hypodiploid ALL cases harbored alterations either in RB1 or in CDKN2A and CDKN2B, suggesting that these are complementary alterations that disrupt the RB1 tumor-suppressor pathway ( Fig. 6a and Supplementary Fig. 14) .
Similarly, 2 of 11 (18.9%) adult cases of low-hypodiploid ALL had RB1 deletions compared to 10 of 106 (9.4%) non-low-hypodiploid ALL cases (Supplementary Fig. 13c and Supplementary Table 19 ).
Alterations of histone and histone-modifier genes
Focal deletions of a histone gene cluster at 6p22 were common in near-haploid ALL (19.1%; Supplementary Fig. 15a) . The minimal region of deletion involved HIST1H2BE, HIST1H4D, HIST1H3D, HIST1H2AD and HIST1H2BF. These deletions have been observed previously in non-hypodiploid ALL, albeit at a lower frequency (8.1% of cases with B-ALL 5 ).
Whole-genome and exome sequencing identified a range of mutations in genes encoding proteins involved in histone modifications (Fig. 6b, Supplementary Note and Supplementary Table 20) . We identified 26 histone-modifier gene mutations in 16 near-haploid ALL cases (64% of the 25 next generation-sequenced near-haploid cases) and 9 mutations in 9 low-hypodiploid ALL cases (60% of 15 cases). The most common target of alteration was the transcriptional coactivator and histone acetyltransferase-encoding gene CREBBP 55 , with 8 of 25 near-haploid cases (32%) harboring a deletion or sequence mutation in this gene (Supplementary Fig. 15b ). Mutations in CREBBP are uncommon at diagnosis in ALL but are enriched at relapse 6 , and this is the first ALL subtype found to have a high frequency of CREBBP mutations at diagnosis. Two of the CREBBP table 12 ). BM, bone marrow; NH, near haploid; LH, low hypodiploid.
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A r t i c l e s substitutions (p.Arg1446Cys and p.Gln1500Pro) occur at residues in the histone-acetyltransferase domain, which is important for the histone acetylase activity of CREBBP 6, 39 . Furthermore, a six-amino-acid deletion in CREBBP overlaps with a deletion in mouse Crebbp that enhances Myc-driven lymphomagenesis 56 . We identified three missense mutations with a predicted deleterious effect in EZH2, the product of which catalyzes trimethylation of histone H3 Lys27 (ref. 57) . Two of these mutations were present in the same relapse sample and were not present at diagnosis (Supplementary Tables 7 and 20) .
Distinct gene expression profiles in hypodiploid ALL
The observation of distinct genomic alterations in near-haploid and low-hypodiploid ALL was recapitulated by gene expression profiling ( Table 1 and Supplementary Table 1) . Near-haploid, low-hypodiploid and near-diploid cases formed discrete clusters in unsupervised hierarchical clustering and principal component analysis (PCA ;  Fig. 2b) . Furthermore, differential expression analysis between near-haploid and low-hypodiploid ALL resulted in >15,000 differentially expressed probe sets (Supplementary Table 21 ). We observed similar PCA clustering when restricting the analyses to probes on chromosomes showing identical patterns of aneuploidy between nearhaploid and low-hypodiploid ALL (Supplementary Fig. 16 ). This indicates that aneuploidy is not responsible for the major differences observed but, rather, there is a global difference in expression profiles between the hypodiploid ALL subgroups. Furthermore, >600 gene sets showed subtype-specific enrichment on gene set-enrichment analysis (Supplementary Table 22 ).
Activation of signaling pathways in hypodiploid ALL
The finding of a high frequency of Ras and RTK signaling lesions suggested that activation of these pathways is important in the pathogenesis of near-haploid ALL. We examined activation of Ras and related signaling pathways in eight near-haploid and six low-hypodiploid tumor xenografts. Flow-cytometric analysis of phosphorylated ERK (pERK), pmTOR and pS6 and assessment of the amount of Ras-GTP showed activated Ras and PI3K signaling in tumors with canonical Ras pathway mutations but also in low-hypodiploid tumors lacking mutations in genes known to regulate Ras and PI3K signaling ( Fig. 7 and Supplementary Fig. 17 ). These findings suggest that alternative mutational mechanisms activate these pathways in low-hypodiploid cases lacking Ras or PI3K pathway mutations. We found deletions of IKZF2 exclusively in low-hypodiploid ALL cases lacking Ras-pathway mutations (Fig. 6a) . To investigate the potential role of IKZF2 inactivation in regulation of Ras signaling, we performed short hairpin RNA (shRNA)-mediated knockdown of Ikzf2 and Ikzf3 in mouse Ba/F3 and Arf −/− pre-B-cell lines (Supplementary Fig. 18 ), which resulted in an increase in the amount of both pERK and pS6 (Supplementary Fig. 19 ). This result suggests that HELIOS and AIOLOS, in addition to their roles within lymphoid development, may also modulate Ras and PI3K signaling. We next examined the potential for targeting Ras, PI3K and mTOR signaling in hypodiploid ALL. We treated the NALM-16 near-haploid cell line and a panel of near-haploid and low-hypodiploid xenograft cells with the MAPK-ERK kinase (MEK) inhibitors PD0325901 and MEK162, the PI3K inhibitor GDC-0941 and the dual PI3K and mTOR inhibitor BEZ235. Notably, MEK inhibition did not affect the proliferation of the samples tested, but the PI3K and dual PI3K and mTOR inhibitors substantially inhibited proliferation of all tumors examined and efficiently attenuated intrinsic PI3K signaling in the NALM-16 cell line (Fig. 7d-f and Supplementary Table 23) , suggesting that inhibition of the PI3K pathway may serve as a new treatment alternative in both near-haploid and low-hypodiploid ALL.
DISCUSSION
Here we report the first genomic analysis of hypodiploid ALL, a leukemic subtype associated with poor outcome that has so far been poorly understood. These analyses indicate that near-haploid and low-hypodiploid ALL are two distinct genetic subtypes characterized by distinct focal deletions and sequence mutations. More than 70% of near-haploid ALL cases harbor activating Ras and RTK signaling alterations, whereas most low-hypodiploid ALL cases harbor TP53 alterations (91.2%), alterations of the lymphoid transcription factor gene IKZF2 (52.9%) or a high frequency (41.2%) of RB1 alterations (Table 1 and Figs. 3-5) . The marked enrichment for Ras-pathway, RB1 and TP53 alterations is unusual in nonhypodiploid ALL and is reminiscent of many solid tumors that more frequently also harbor aneuploid genomes [58] [59] [60] .
The markedly high frequency of TP53 alterations in both pediatric and adult low-hypodiploid ALL (91.2% and 90.9%, respectively) suggests that alteration of this gene is an important event in the pathogenesis of low-hypodiploid ALL. Furthermore, almost half of the TP53 mutations identified in pediatric low-hypodiploid ALL were present as heterozygous mutations in remission bone marrow or peripheral blood and in purified normal T-cell populations, and most of these are known LFS-associated mutations 40 (Supplementary Table 18 ). Notably, we confirmed the inherited origin of the TP53 mutation identified in one pediatric low-hypodiploid case by studying nonhematopoietic cells (Fig. 4c,d and Supplementary Note). In addition, two of the cases have a known familial history of cancer; the familial cancer history for the other cases is unknown (data not shown). Together, these data strongly suggest that the TP53 mutations are inherited and that low-hypodiploid ALL is a manifestation of LFS.
Catastrophic DNA rearrangements referred to as chromothripsis 61 have recently been linked with inherited TP53 mutations in pediatric brain tumors 62 . We observed no evidence of chromothripsis in TP53-altered hypodiploid ALL ( Fig. 1 and Supplementary Figs. 2 and 3) . TP53 mutations have also been associated with aneuploidy [63] [64] [65] and may contribute to the development of aneuploidy in low-hypodiploid ALL. However, the genetic basis of aneuploidy in near-haploid ALL, which lack TP53 mutations, is unknown, and our genome-wide analyses have not identified any other recurrent gene alterations that may contribute to the development of aneuploidy.
RB1 is inactivated in a wide variety of solid tumors 60, 66 and hematopoietic malignancies but is not commonly mutated in B-ALL 39 . In contrast, deletion of the CDKN2A and CDKN2B loci is common in ALL and may substitute for RB1 and TP53 alterations 3, 39 . Lowhypodiploid ALL is thus notable for the high frequencies of TP53 and RB1 inactivation in both pediatric and adult cases. Most RB1 alterations were mutually exclusive with deletions of CDKN2A and CDKN2B, whereas TP53 mutations mostly occurred together with deletions at these loci ( Fig. 6a and Supplementary Fig. 14) . This suggests that alteration of p53 provides a survival advantage for the leukemic cells that cannot be compensated for by loss of CDKN2A, whereas loss of RB1 or of CDKN2A or CDKN2B represents alternative mechanisms of inactivating the RB1 tumor-suppressor pathway.
The finding of IKZF2 deletions in 52.9% of low-hypodiploid ALL and IKZF3 alterations in 13.2% of near-haploid ALL was unexpected. IKZF1 is essential for lymphopoiesis 46 , and alterations of this gene are associated with poor outcomes in B-ALL 5 . Less is known about the roles of IKZF2 and IKZF3 in lymphoid development and leukemogenesis. The distinct mutational patterns of the IKAROS gene family in different ALL subtypes may indicate that either the different gene-family members have distinct roles in different ALL subtypes, the different ALL subtypes have cells of origin from a developmental npg A r t i c l e s stage in which a certain IKAROS gene-family member is expressed or both. The low frequency of antigen-receptor rearrangements, reduced expression of CD19, similarity of the transcriptional profile to immature mouse lymphoid progenitors and expression of mouse Ikzf2 in common lymphoid progenitors and pre-pro-B cells together suggest that low-hypodiploid ALL arises from transformation of a less mature lymphoid progenitor than near-haploid or non-hypodiploid ALL (Supplementary Figs. 11 and 12) .
In previous studies, mouse Aiolos has been shown to interact with Ras, potentially acting as an inhibitor 67 . We found that IKZF2 and Ras-pathway alterations are usually mutually exclusive (Fig. 6a) , and there is evidence of activation of downstream Ras and PI3K signaling in low-hypodiploid ALL in the absence of known activating mutations ( Fig. 7 and Supplementary Fig. 17) . Furthermore, we observed higher amounts of pERK and pS6 after knockdown of Ikzf2 and Ikzf3 in cell lines (Supplementary Fig. 19 ). This raises the possibility that HELIOS and AIOLOS are modulators of Ras and PI3K signaling and that inactivation of these gene products may drive tumor cell proliferation. In addition, PI3K and mTOR inhibitors potently inhibited proliferation of both near-haploid and low-hypodiploid cells ex vivo. Consequently, therapeutic targeting of PI3K and mTOR should be further investigated as a therapeutic modality in the treatment of these high-risk ALL subtypes.
ONLINE METHODS
Patients and samples. We studied 124 pediatric patients with hypodiploid ALL treated according to St. Jude Children's Research Hospital (SJCRH; n = 29) and Children's Oncology Group (COG; n = 95) protocols. Relapse material was available for 5 cases, and 89 cases had a matched remission sample (Supplementary Table 1) . We also studied a cohort of 117 adult ALL cases, including 11 lowhypodiploid ALL cases (Supplementary Table 2) .
Informed consent was obtained in accordance with the Declaration of Helsinki. Study approval was obtained from the SJCRH and COG institutional review boards (IRBs) and the IRBs of the Royal Adelaide Hospital.
Mononuclear cells were purified from bone marrow or peripheral blood by density gradient centrifugation and cryopreserved in liquid nitrogen. Diagnostic samples were characterized as hypodiploid ALL samples by karyotyping and DNA index measurement.
DNA was directly extracted from tumor samples with >70% blasts and from remission samples using either phenol-chloroform or a DNA Blood Mini Kit (Qiagen), and DNA integrity was assessed by agarose gel electrophoresis. Tumor samples with <70% blasts and sufficient material were flow sorted before DNA extraction using FACSVantage SE flow cytometers and phycoerythrin (PE)-labeled CD19 (BD Biosciences) and FITC-labeled CD45 (Life Technologies) antibodies. Tumor samples from cases harboring TP53 mutations lacking a matched remission sample were flow sorted using CD45-FITC and allophycocyanin (APC)-labeled CD7 (Life Technologies) antibodies to obtain nonleukemic T cells to test the somatic status of the mutations. DNA was whole-genome amplified using the Repli-G mini kit (Qiagen). DNA concentrations were measured using a NanoDrop ND-1000 spectrophotometer or fluorometrically by the Quant-iT BR kit (Life Technologies) using a Synergy HT (BioTek). RNA was extracted from tumor samples using TRIzol (Life Technologies). Next-generation sequencing. Twenty cases underwent whole-genome sequencing (WGS) of tumor and matched nontumor DNA, and 20 cases underwent whole-exome sequencing (WES, Agilent SureSelect Human All Exon 50 MB). DNA and RNA library preparations and paired-end sequencing were performed using either Illumina GAIIx or HiSeq 2000 analyzers, as described 15, 70, 71 .
Analysis of sequence and structural variants was performed as described 15 . Validation was performed using either Roche 454 FLX sequencing or Sanger sequencing after PCR amplification of whole-genome amplified tumor and matched normal DNA.
For the mRNA sequencing data from the cell line NALM-16, putative variants were compared to a database of variants identified in 254 nontumor samples sequenced as part of the SJCRH-Washington University Pediatric Cancer Genome Project (PCGP 72 ), as well as variants present in dbSNP 73 (excluding known cancer variants in OMIM and local databases). The remaining variants were also compared with exome variants identified by the National Heart, Lung, and Blood Institute (NHBLI) Exome Sequencing Project (Exome Variant Server). Data are presented in Supplementary Table 25. Deleterious germline variant analysis. New, nonsilent germline coding variants were identified as described 15 . Probable deleterious variants were identified if they met one of the following criteria: (i) match any validated somatic mutation; (ii) predicted truncating variants in known cancer genes (using a combined list of CancerGeneCensus genes, downloaded on 22 March 2011, and 120 frequently mutated genes in childhood ALL 39 ); or (iii) overlap with sites (either chromosome coordinates or amino acid) in which confirmed somatic variants have been reported by COSMIC (Catalogue Of Somatic Mutations In Cancer). Variants initially discovered by the somatic pipeline but validated as germline were also included in the search. To further filter out common polymorphisms caused by deficiency in the current human assembly, we compared the selected germline variants with common germline variants identified by the NHLBI Exome Sequencing Project, and an internal database of germline variants collected from PCGP. We further removed variants present in germline but absent in tumor as a result of aneuploidy. SNP microarrays. Samples were genotyped using Affymetrix SNP 6.0 microarrays according to the manufacturer's instructions. CEL files were generated using GeneChip Command Console Software. SNP calls were generated using Genotyping Console (Affymetrix) and the Birdseed v2 algorithm with default parameters, with at least 50 arrays in each analysis.
Array normalization and copy-number inference were performed according to a published workflow 3, 27 . The importance of correct normalization is clearly exemplified by the highly aneuploid hypodiploid ALL samples ( Supplementary  Fig. 20) . Normalized data were viewed in dChip 74 , and regions with abnormal copy number were identified computationally by circular binary segmentation (CBS) 75 and analyzed as described 3, 27 .
Recurrent focal deletions were validated by genomic PCR and/or RT-PCR, followed by Sanger sequencing. Oligonucleotide primers for PCR amplification were designed using Primer 3 (ref. 76) . Primers used for mapping the NF1 exons 15-35 deletion are present in Supplementary Table 26 .
Targeted gene resequencing. Gene resequencing was performed for all 124 diagnosis cases, two relapse cases (SJHYPO056-R and SJHYPO117-R) and the hypodiploid cell line NALM-16 for the genes listed in Supplementary  Table 9 . Primer sequences are provided in Supplementary Table 26 . Sequencing was performed by PCR of whole genome-amplified DNA, followed by sequencing using 3730 × l instruments (Applied Biosystems) as described 6 . SNVs were detected by SNPdetector 77 and PolyScan 78 and validated by sequencing of both tumor and, where available, matched nontumor samples. Variations identified in unpaired tumor samples were compared to online databases and to a local database of sequence variation.
Gene expression profiling. Gene expression profiling was performed using Affymetrix GeneChip HT HG-U133+ PM microarrays for human specimens (samples listed in Supplementary Table 1 ) and MG-430 2.0 microarrays for Hardy Fractions from mouse cells (details listed in Supplementary  Table 27 ), according to the manufacturer's instructions. Arrays with outlier relative log expression metric were excluded from the data depository and downstream analysis. Statistical analyses, PCA and unsupervised hierarchical clustering were performed using R 2.13.0 (ref. 60) , Bioconductor 2.6 (ref. 61) and Spotfire Decision Site 9.1.1 (Tibco). For HT HG-U133+ arrays, all samples were normalized by the RMA algorithm. Probe sets not passing the background signal (twice the average signal on the control probes with different GC content) across all samples were excluded for differential expression analysis, where limma 62 with estimation of false-discovery rate (FDR) 63 was performed between experimental subgroups. Probe sets below an FDR cutoff of 0.05 were deemed differentially expressed. Weighted pair-group method with arithmetic mean clustering with Euclidean distance was performed using the 10,000 probe sets with the highest s.d. across samples. For MG-430 2.0 arrays, gene expression signals were scaled to a median value of 500 using the Affymetrix MAS 5.0 algorithm. Probe sets with absent calls for all samples were excluded, and probe set signals were variance stabilized by adding the number 32 and subsequently log 2 transformed. The top 50, 100, 250 and 500 gene signatures for each Hardy fraction were identified using limma, and gene set enrichment analysis (GSEA) 79 was used to examine the enrichment of the Hardy fraction gene sets for each hypodiploid ALL subgroup. Gene sets with <10 or >500 genes were excluded, and significantly enriched gene sets after 1,000 permutations at an FDR of <0.25 are reported.
Immunohistochemical analyses. Immunohistochemistry of human and mouse tissues was performed using routine techniques, hematoxylin-and-eosin staining and appropriate primary antibodies.
Generation of xenografted mice. The mouse studies were approved by the SJCRH Institutional Animal Care and Use Committee. Primary leukemic cells were transplanted by tail vein injection into sublethally irradiated (250 cGy) immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice (two or three mice npg per tumor; The Jackson Laboratory). Engraftment was analyzed by biweekly retro-orbital bleeds followed by flow-cytometric analysis of human peripheral blood cells stained for human CD45-FITC, CD19-PE and CD7-APC and for mouse cells stained for CD45-PE-Cy7. Mice were killed upon signs of disease, and tumors were characterized histologically, immunophenotypically (immunophenotypic markers as above) and by genomic profiling by Affymetrix SNP6.0 microarrays for a subset of samples (Supplementary Note and Supplementary Figs. 21 and 22) . FACS analysis. Cell lines were starved in serum-free medium for 5 h before stimulation with phorbol 12-myristate 13-acetate (PMA) (50 nM; 15 min) or treatment with BEZ235 or GDC-0941 (0.3 µM and 0.7 µM, respectively (IC 50 values for NALM-16); 1 h). Cell lines and splenocytes and bone marrow cells from xenografted mice were fixed with 2% paraformaldehyde and permeabilized with 90-95% methanol before staining with antibodies (Supplementary Table 28 ) and analysis on LSR II or FACS Calibur (Becton Dickinson). Data were collected using DIVA or CellQuest software (Becton Dickinson) and analyzed using FLOWJO (Tree Star) and Cytobank.
Immunoblotting and Ras-GTP assay. Cells were lysed, and protein concentrations were determined using the BCA Protein Assay Kit (Pierce). Samples were separated on Criterion polyacrylamide (Bio-Rad) or NuPAGE (Life Technologies) gels and transferred to Immobilon-P (Millipore) or polyvinylidene fluoride (PVDF) (Life Technologies) membrane. After staining with the respective antibodies (Supplementary Table 28) , target proteins were visualized using ECL (Amersham Biosciences), ECL plus (GE Healthcare) or the Femto Chemiluminescent Kit (Thermo Fisher). Ras-GTP amounts were measured using a Raf-Ras binding domain (RBD) bead pull-down assay, as described 80, 81 .
Ex vivo drug studies. Cell viability and proliferation of bone marrow cells obtained from xenografted mice was determined using AO/PI staining (Nexcelom Bioscience) and WST-1 reagent (Roche) according to manufacturer's instructions. Cells were treated with BEZ235, GDC-0941, MEK162 or PD0325901 at increasing concentrations as indicated in Supplementary Table 23 for 72 h. The concentration inhibiting cell proliferation by 50% compared with control cells (IC 50 ) was determined using GraphPad Prism 5.0 (GraphPad Software).
Outcome analysis. Event-free survival (EFS) was defined as the time from diagnosis until the date of relapse or until the last follow-up date for all eventfree survivors. Death was treated as a competing risk. Associations between genetic variables and EFS were estimated by the methods of Kaplan and Meier. Standard errors were calculated as described 82 . The Mantel-Haenszel test was used to compare EFS estimates for patients with and without lesion at each locus 83 . The proportional hazards model of Fine and Gray was used to adjust for age, presentation leukocyte count, aneuploidy subgroup and levels of minimal residual disease (MRD) 84 . Analyses were performed using R (http://www.r-project.org/) 85 , SAS v9.1.2 (SAS Institute) and SPLUS 7.0 (Insightful Corp.). To evaluate associations between genetic alterations and MRD, and hypodiploid ALL subgroup and MRD, MRD data were converted into an ordinal variable (<0.01% (negative) and ≥0.01% (positive)), and association analyses were performed using the χ 2 test (FREQ procedure, SAS) with estimation of false discovery rate (MULTTEST, SAS). Significantly associated variables were adjusted for age, presentation leukocyte count and genetic subtype using logistic regression. Data are presented in the Supplementary Note and Supplementary Tables 29-34. 
